# READDI

**Rapidly Emerging Antiviral Drug Development Initiative**

THE UNIVERSITY
*of* NORTH CAROLINA
*at* CHAPEL HILL

# Without bold action now, the next pandemic is inevitable

- Novel viruses are emerging more frequently
- Viruses can emerge from anywhere
- The costs are staggering
- Response to COVID-19 continues to reveal multiple system failures

**The world urgently needs a better solution.**

# The current system is not optimized for pandemics

- Pharma is reluctant to invest in products with no obvious market
- University research funding (e.g. NIH) is project-based aimed at point solutions
- Governments cycle between panic and neglect

> **To achieve pandemic preparedness, we must re-engineer antiviral therapeutic development and delivery.**

# The solution is READDI

READDI brings together the world's best scientific and business minds to proactively develop and deliver novel antiviral drugs BEFORE the next virus creates another global catastrophe.

# READDI is a public-private partnership

CEPI

**Vaccines**

Coalition for Epidemic Preparedness

CARB-X

**Antibiotics**

Combating Antibiotic-Resistant Bacteria

READDI

**Antivirals**

Rapidly Emerging Antiviral Drug Development Initiative

# What will READDI do?

## Accelerate new antiviral drug development

Target factors that viruses need to replicate

Fund and facilitate projects at all stages

## Aggregate and advance existing assets

Identify promising antiviral compounds shelved by industry

Develop stalled antivirals from academic labs

## Expedite treatment availability

Prepare Phase II & III trial design

Identify manufacturing partners in advance

# The READDI approach




## Preparation

- Fund cross-sector science teams
- Complete antiviral drug development through Phase I (unless existing market opportunity)
- Put promising new and existing compounds on the shelf

## Streamlined Execution

- Licensing
- Clinical trial design completed
- Trial sites designated
- Private sector partners in place

# We're already collaborating for success

THE UNIVERSITY of NORTH CAROLINA at CHAPEL HILL

## Industry Partners

- janssen
- PHARMACEUTICAL COMPANIES OF Johnson & Johnson
- Calibr at Scripps Research
- Pfizer
- RTI INTERNATIONAL
- Takeda
- LOVELACE BIOMEDICAL
- Patheon

## University Partners

- UAB THE UNIVERSITY OF ALABAMA AT BIRMINGHAM
- VANDERBILT UNIVERSITY
- UCL
- Washington University in St. Louis
- MONASH University
- University of Colorado Boulder
- UNIVERSITY OF TORONTO
- UNIVERSITY OF OXFORD
- OREGON HEALTH & SCIENCE UNIVERSITY

## Strategic Partners

- DNDi Drugs for Neglected Diseases initiative
- SGC
- sas
- DEERFIELD Advancing Healthcare
- NC Policy Collaboratory
- NIH National Institutes of Health

# The research team is already at work

- 20+ active projects with partners from around the world
- Focus on multiple viral families with high pandemic potential

**Project example:**

- COVID-19 – Repurpose kinase inhibitors as SARS2 antiviral drugs

THE UNIVERSITY of NORTH CAROLINA at CHAPEL HILL

SGC

Calibr at Scripps Research

# When the next virus emerges

On Day 1 we will have:

- Effective antiviral therapies through Phase I
- Phase II & III clinical trials designed
- Established manufacturing plan
- Helped facilitate global response and equitable distribution

# Will you help us prepare for the next pandemic?

**Contact**

Nat Moorman: nmoorman@med.unc.edu
John Bamforth: johnph@email.unc.edu

READDI